Skip to main content

Table 2 Clinical outcome summary scores from clinician interview for patients with psychosis

From: Evaluation of outcomes for psychosis and epilepsy treatment delivered by primary health care workers in Nepal: a cohort study

  Program (n = 53) Control (n = 21) ANCOVA Full cohort (n = 74)
Mean SD Mean (SD) Effect size
F, partial eta2
P-value* Mean (SD) Effect size
Z, r
P-value**
PANSS positive and negative < 0.01, < 0.01 0.96    6.87, 0.80 < 0.0001
Baseline 25.5 12.1 24.9 11.9    25.3 − 12   
end point 7.9 7.4 10.3 12.2    8.6 − 9   
Δ score − 17.6 12.5 − 14.6 14.1    − 16.8 − 12.9   
PANSS positive 1.22, 0.02 0.22    6.87, 0.80 < 0.0001
Baseline 11.6 6.8 13.1 5.7    12 6.5   
end point 2.7 3.3 3.7 4.6    3 4.6   
Δ score − 8.9 7.7 − 9.3 7.5    − 9 7.5   
PANSS negative 2.16, 0.03 0.69    6.42, 0.75 < 0.0001
Baseline 13.9 7.3 11.8 7.4    13.3 7.4   
end point 5.2 5.3 6.6 7.7    5.6 6.1   
Δ score − 8.7 7 − 5.2 8    − 7.7 7.4   
HAM-D       0.02, < 0.01 0.27    6.02, 0.70 < 0.0001
Baseline 15.6 7.2 16.3 7.8    15.8 7.3   
end point 7.7 4.5 8.0 6.7    7.8 6.7   
Δ score − 7.8 8.0 − 8.4 11.3    − 8.0 9.0   
  1. HAM-D Hamilton Depression Scale, PANSS positive and negative syndrome scale
  2. * P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
  3. ** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)